Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice.

Islet transplantation represents a potential cure for type 1 diabetes, yet persistent autoimmune and allogeneic immunities currently limit its clinical efficacy. For alleviating the autoimmune destruction of transplanted islets, newly diagnosed NOD mice were provided a single intramuscular injection of recombinant adeno-associated viral vector encoding murine IL-10 (rAAV-IL-10) 4 weeks before renal capsule delivery of 650 syngeneic islets. A dose-dependent protection of islet grafts was observed. Sixty percent (3 of 5) of NOD mice that received a transduction of a high-dose (4 x 10(9) infectious units) rAAV-IL-10 remained normoglycemic for at least 117 days, whereas diabetes recurred within 17 days in mice that received a low-dose rAAV-IL-10 (4 x 10(8) infectious units; 5 of 5) as well as in all of the control mice (5 of 5 untreated and 4 of 4 rAAV-green fluorescent protein-transduced). Serum IL-10 levels positively correlated with prolonged graft survival and were negatively associated with the intensity of autoimmunity. The mechanism of rAAV-IL-10 protection involved a reduction of lymphocytic infiltration as well as induction of antioxidant enzymes manganese superoxide dismutase and heme oxygenase 1 in islet grafts. These studies support the utility of immunoregulatory cytokine gene therapy delivered by rAAV for preventing autoimmune disease recurrence in transplant-based therapies for type 1 diabetes.

[1]  Tzong-Shyuan Lee,et al.  Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice , 2002, Nature Medicine.

[2]  Y. Liu,et al.  Strain-based Genetic Differences Regulate the Efficiency of Systemic Gene Delivery as Well as Expression* , 2002, The Journal of Biological Chemistry.

[3]  A. M. Shapiro,et al.  Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice , 2002, Diabetologia.

[4]  A. Cooke,et al.  Cutting Edge: Interactions Through the IL-10 Receptor Regulate Autoimmune Diabetes1 , 2001, The Journal of Immunology.

[5]  T. Flotte,et al.  Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  F. Bach,et al.  Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. , 2001, Diabetes.

[7]  C. Ricordi,et al.  Factors influencing Islet of Langerhans graft function and monitoring. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[8]  D. Schoenfeld,et al.  Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. , 2001, The Journal of clinical investigation.

[9]  Y. Rojanasakul,et al.  Interleukin-10-mediated inhibition of free radical generation in macrophages. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[10]  S. Kato,et al.  Strain-dependent antibody response induced by DNA immunization. , 2000, Immunology letters.

[11]  D. Heistad,et al.  IL-10 deficiency increases superoxide and endothelial dysfunction during inflammation. , 2000, American journal of physiology. Heart and circulatory physiology.

[12]  R. Pavlovich,et al.  Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. , 2000, Diabetes.

[13]  G. Prud’homme.  Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors , 2000, The journal of gene medicine.

[14]  N. Sarvetnick,et al.  IL-10 deficiency does not inhibit insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic mouse. , 2000, Cellular immunology.

[15]  A. Choi,et al.  Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway , 2000, Nature Medicine.

[16]  O. Simell,et al.  Cytokine Balance and Lipid Antigen Presentation in the NOD Mouse Pancreas During Development of Insulitis , 2000, Pancreas.

[17]  S. Pestka,et al.  A Single Amino Acid Determines the Immunostimulatory Activity of Interleukin 10 , 2000, The Journal of experimental medicine.

[18]  C. Janeway,et al.  The role of CD4 vs. CD8 T cells in IDDM. , 1999, Journal of autoimmunity.

[19]  M. Atkinson,et al.  The NOD mouse model of type 1 diabetes: As good as it gets? , 1999, Nature Medicine.

[20]  B. Woda,et al.  NOD mice have a generalized defect in their response to transplantation tolerance induction. , 1999, Diabetes.

[21]  T. Flotte,et al.  Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Kasuga,et al.  Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. , 1998, The Journal of clinical investigation.

[23]  J. Rabinowitz,et al.  Adeno-associated virus expression systems for gene transfer. , 1998, Current opinion in biotechnology.

[24]  J. Miyazaki,et al.  Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. , 1998, Human gene therapy.

[25]  A. Krętowski,et al.  Decreased In Vitro and IL-10 Production by Peripheral Blood in First Degree Relatives at High Risk of Diabetes Type-I , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[26]  A. Rabinovitch.  An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. , 1998, Diabetes/metabolism reviews.

[27]  R. Rajotte,et al.  TNF-alpha down-regulates type 1 cytokines and prolongs survival of syngeneic islet grafts in nonobese diabetic mice. , 1997, Journal of immunology.

[28]  G. Korbutt,et al.  Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice. , 1997, Transplantation.

[29]  D. Eizirik,et al.  IL‐1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non‐obese diabetic (NOD) mice , 1997, Clinical and experimental immunology.

[30]  M. Matzuk,et al.  Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  N. Sarvetnick,et al.  The paradoxical effects of interleukin 10 in the immunoregulation of autoimmune diabetes. , 1996, Journal of autoimmunity.

[32]  R. Rajotte,et al.  COMBINED THERAPY WITH INTERLEUKIN‐4 AND INTERLEUKIN‐10 INHIBITS AUTOIMMUNE DIABETES RECURRENCE IN SYNGENEIC ISLET‐TRANSPLANTED NONOBESE DIABETIC MICE ANALYSIS OF CYTOKINE MRNA EXPRESSION IN THE GRAFT , 1995, Transplantation.

[33]  J. Miyazaki,et al.  Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. , 1994, International immunology.

[34]  R. Rajotte,et al.  Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: interleukin 2 and interferon gamma mRNA expression correlate with graft rejection and interleukin 10 with graft survival , 1994, Diabetologia.

[35]  M. Monahan,et al.  Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. , 1994, Clinical immunology and immunopathology.

[36]  A. Rabinovitch.  Immunoregulatory and Cytokine Imbalances in the Pathogenesis of IDDM: Therapeutic Intervention by Immunostimulation? , 1994, Diabetes.

[37]  J. Lakey,et al.  BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice. , 1994, Transplantation.

[38]  N. Sarvetnick,et al.  Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice , 1994, The Journal of experimental medicine.

[39]  B. Hall,et al.  Cells mediating allograft rejection. , 1991, Immunological reviews.

[40]  D. Sutherland,et al.  Recurrence of Disease in Pancreas Transplants , 1989, Diabetes.

[41]  F. Bach,et al.  Carbon Monoxide Protects Pancreatic -Cells From Apoptosis and Improves Islet Function/Survival After , 2002 .

[42]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[43]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.